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Alzheimer’s disease (AD) is characterized by the progressive and selective loss of neurons and 
synapses. This debilitating disease was estimated to affect 33.9 million patients worldwide in 2011, a 
number that is expected to triple over the next 40 years (1). It has been shown that a combination of 
several processes, including extracellular deposition of amyloid-beta (Aβ) plaques and the formation 
of intracellular neurofibrillary tangles (NFTs) composed of hyper-phosphorylated tau proteins, in 
the brain are involved in the declining cognitive processes associated with AD (2). While dysfunction 
of the aforementioned biological processes starts from Braak stage I (preclinical AD), it is not until 
the majority of the neocortex is severely affected by neurofibrillary changes (Braak stages V–VI) that 
patients are ultimately diagnosed with dementia (3).
Notably, clinical studies have found numerous links between AD and age-related macular 
degeneration (AMD). AMD is a progressive macular neurodegenerative disease and is the most 
common cause of irreversible blindness, being estimated to affect 196 million people globally by the 
year 2020 (4). Although AMD is largely considered a retinal disease, the emerging epidemiological 
links between cognitive impairment, such as those observed in AD patients, and AMD patients are 
significant (5). In fact, it appears that cognitive impairment and early AMD may share numerous 
common age-related pathways and risk factors (6–8). Using logistic regression models that control 
for age, sex, race, education, systolic blood pressure, total cholesterol level, diabetes mellitus, smoking 
status, and ApoE genotype, it has been demonstrated that persons with mild cognitive impairment 
were more likely to have AMD compared to healthy patients (odds ratio of 2.00). It also appears that 
the reverse is true, with the prevalence of mild cognitive impairment being higher in AMD patients 
compared to control groups (52.4 vs. 26.8%, p < 0.001), with an odds ratio of 3.127 after adjusting 
for age, education, and visual acuity (8).
The similarities between AD and AMD are not that surprising as the retina is an integral part 
of the central nervous system (CNS), being derived from the neural tube much like other regions 
of the brain. AMD and AD also have many parallel characteristics, which have been extensively 
reviewed by Ohno-Matsui (9). One of the common pathological hallmarks of these two diseases is 
the extracellular deposits that are highly enriched with Aβ42. In AMD, the deposits, called drusen, 
are found between the retinal pigmented epithelium (RPE) and Bruch’s membrane. In AD, the 
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deposits found in the brain are referred to as senile plaques and 
are localized primarily to the hippocampus and cortex. Detailed 
proteomic analyses of their molecular components have shown 
similarities between drusen and senile plaques, and proteins 
such as Aβ, tau, proteoglycans, and inflammatory mediators 
have been detected in both. These findings suggest that similar 
pathways could potentially be involved in the etiology of both 
AMD and AD.
Aβ42 peptides and related amyloidogenic molecules are 
thought to impact AMD and AD pathology in the following ways: 
(i) through progressive distortion of the structure and function of 
the retinal/neocortical architecture; (ii) by promoting mitochon-
drial dysfunction and the generation of reactive oxygen species 
(ROS) leading to the oxidation of retinal/neuronal components 
and apoptosis; (iii) by activating microglial cells, the chief innate-
immune “phagocytosis” and “scavenging” cells of the retina/brain 
and CNS; (iv) by activating microglial-mediated pathological 
pathways, which have subsequent pro-inflammatory responses. 
It is important to note that all four of these pathological sequels 
may occur concurrently during the onset and propagation of 
AMD/AD (10), and recent research has indicated that AD-like 
pathology may be accelerated by cigarette smoking (11).
Cigarette smoking (CS) has long been known to be an envi-
ronmental age accelerator (12). It is estimated that by the year 
2020 the number of annual tobacco-related deaths will reach 7.5 
million, which will account for approximately 10% of all fatalities 
(13). According to the 2011 WHO statistics (13), tobacco use was 
the second most significant risk factor for developing a number 
of non-transmissible diseases. Interestingly, contrasting reports 
have been published concerning the associations between CS and 
the risk of developing AD-like pathology or even AD in different 
populations. One study indicated that while CS renders protec-
tion from AD in Western populations, it appears to increase the 
risk in Asian populations. After adjusting for heterogeneity, heavy 
smoking (greater than 55.5 packs per year) does appear to con-
sistently increase the risk of developing AD (14). Various animal 
studies also suggest that CS induces neuropathological changes 
that can accelerate the progression of AD (15, 16). Furthermore, 
in the brain matter of cigarette smoke-exposed Lewis rats, the 
expression of genes encoding for pro-oxidant iNOS, NOX4, dual 
oxidase1, and p22phox was increased (17). In the hippocampus 
of cigarette smoke-exposed SD rats, the oxidative DNA damage 
marker 8-hydroxyguanosine was also increased (15). Oxidative 
stress can also activate JNK signaling leading to tau phosphoryla-
tion and apoptosis. In fact, after 8 weeks of exposure to cigarette 
smoke, the level of phospho-JNK was increased along with the 
levels of tau hyperphosphorylation at residues Thr231, Thr205, 
and Ser404. Reduced expression of various synaptic proteins 
(e.g., synapsin-1, synaptophysin) and cytoskeleton-related pro-
tein (e.g., tubulin, drebrin) were also detected in these cigarette 
smoke-exposed rats, indicating possible synaptic degeneration 
and axonal deficits (15). Furthermore, in a mouse model of 
AD, cigarette smoke was also observed to exacerbate amyloid 
pathology, resulting in increased amyloid deposition (which 
subsequently led to the formation of new plaques) and acceler-
ated maturation of the amyloid deposits after only 4 months of 
exposure (16). 
Compared to the conflicting epidemiological evidence linking 
AD and CS, CS has been shown to be one of the major modifi-
able risk factors for AMD, almost doubling the risk of developing 
AMD while also promoting the progression of the disease from 
the atrophic to the neovascular form (11, 18, 19). These accel-
erated changes are likely propagated by the toxic compounds 
found in cigarette smoke, many of which have been shown to 
induce oxidative stress and/or decrease free radical scavengers 
(20). In fact, cigarette smoke extract (CSE) has been shown to 
significantly reduce the viability of RPE-19 cells and primary 
RPE cells via alterations to mitochondrial integrity and increased 
lipid peroxidation (21). Moreover, CS promotes molecular and 
pathological changes that may establish an ideal microenviron-
ment for the development of AMD, vascular inflammation, 
endothelial dysregulation, oxidative damage, toxic damage, as 
well as histopathological changes in the RPE, Bruch’s membrane, 
and choriocapillaris (11). This hypothesis is supported by pre-
vious studies showing that 6  months of exposure to cigarette 
smoke induces changes in these ocular tissues in a mouse model, 
which mimic the changes that occur in human AMD (22, 23). 
Importantly, the smoking-related changes leading to accelerated 
AMD can, to some extent, be reversed when the patient stops 
smoking if detected early (19).
Clinically, AMD progression is typically monitored by ana-
lyzing the deposition of drusen and changes in the pigmentation 
of the RPE (24). Aβ assemblies are the most prevalent in retinas 
with moderate-to-high drusen loads in the advanced stages 
of AMD (25), which potentially already involve irreversible 
changes in the patient’s vision. While most AMD studies focus 
on drusen formation in the outer retina, some consideration has 
been given to early changes occurring in the inner retina. Anti-
astrocyte and anti-retinal autoantibodies have been detected in 
the sera from patients with early forms of AMD, which suggest 
that changes in the neural retina may also be an early feature of 
the disease. Abnormalities in the electrooculograms (EOGs) and 
electroretinograms (ERGs) measured for these retinas also indi-
cate global retinal dysfunction (26). Notably, both normal aging 
and AMD appear to affect the rod-mediated mfERG measure-
ments (27) and alter neuronal transmission at the postreceptoral 
level. These functional ERG changes may indicate anatomic and 
functional plasticity in the synaptic circuity, possibly at the 
level of photoreceptor-bipolar synapses. In light-damaged rat 
eyes, which mimic dry AMD, there also appears to be exten-
sive dendritic remodeling and extension of the neurons (28). 
Moreover, neurons in AMD retinas have the capacity to remodel 
by sprouting processes and re-forming synaptic complexes with 
their appropriate targets (29). This remodeling was evident 
before any evidence of neuronal loss and was accompanied by 
the reconnection of the presynaptic elements to the postsynaptic 
bipolar neurons. Thus, if diagnosed early, say before the drusen 
deposition in the outer retina, AMD could in fact be prevented 
and/or reversed.
It is in our opinion that in order to diagnose AMD in ciga-
rette smokers early enough to prevent lasting damage, clinicians 
should focus on the early changes occurring in the retina. To do 
so, the links between AMD and AD can be exploited to some 
extent, particularly for the development of diagnostic tools. For 
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example, the techniques presently being developed and optimized 
to detect structural and functional changes in AD patients could 
be invaluable for early AMD diagnosis. In fact, the retinas of AD 
patient have also been shown to be affected by the disease, with 
Aβ deposition being detected along with retinal ganglion cell 
degeneration and decreased thickness of the retinal nerve fiber 
layer (30), suggesting that the inner retina is primary location of 
damage in AD patients. Although the location of Aβ42 deposition 
and the cell type affected in the retinas of AMD patients appear 
to be different compared to AD patients, similar detection tools 
could be utilized to diagnose AMD before permanent vision loss. 
It is essential to conduct longitudinal animal studies investigating 
the neuronal changes of the retina as well as the RPE, Bruch’s 
membrane, and choidocapillaries together with retinal function 
tests in order to demonstrate the role these early neuronal changes 
might also play in AMD pathogenesis. Current animal models 
can allow us to investigate correlation of these functional changes 
with the histopathology hallmarks in eyes exposed to CS. Then, 
we can apply our research findings for non-invasive imaging 
method to monitor disease progression, contributing to clinical 
investigations. The information gleaned from these studies may 
also elucidate additional links between AD and AMD in addi-
tion to potentially highlighting biomarkers involved in the early 
changes occurring during both diseases, in both the brain and 
retina. Ultimately, we believe it is likely that the link between the 
brain and retina will play an essential role in aiding researchers 
in the development of diagnostic tools for CS-induced AMD. The 
current literature and continued research concerning the early 
neuronal changes in both the brain and retinas of AD patients and 
animal models indicate that they could be used as a good model 
of the early retinal changes in CS-induced AMD. It is our hope 
that remarking on this  phenomenon encourages additional 
research into the utilization of these previous reports to mediate 
early diagnosis of AMD (i.e., Aβ, tau,  inflammation, microglial 
activation), and that emerging treatments for AD (anti-amyloid, 
anti-tau) in conjunction with reduced CS might be useful for the 
treatment of AMD.
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